Raia Drogasil SA Stock Sao Paulo
Stocks
DROG3
BRDROGACNOR1
Drug Retailers
OTC Markets Traded|
End-of-day quote
Other stock markets
|
||
| - BRL | - |
|
| 21/05 | Brazil's GPA sells stake in Stix for 23 million reais, ends joint venture | RE |
| 07/05 | Raia Drogasil S.A., Q1 2026 Earnings Call, May 06, 2026 |
| Market Cap | 32.44B 6.34B 5.54B 5.11B 4.71B 8.88B 611B 9.08B 61.11B 24.03B 299B 23.81B 23.29B 1,029B | P/E 2026 * |
21.7x | P/E 2027 * | 16x |
|---|---|---|---|---|---|
| Enterprise Value | 40.5B 7.92B 6.92B 6.38B 5.88B 11.09B 762B 11.34B 76.3B 30.01B 373B 29.73B 29.08B 1,285B | EV / Sales 2026 * |
0.89x | EV / Sales 2027 * | 0.78x |
| Free-Float |
73.24% | Yield 2026 * |
1.95% | Yield 2027 * | 2.5% |
Last Transcript: Raia Drogasil SA
| Manager | Title | Age | Since |
|---|---|---|---|
Renato Raduan
CEO | Chief Executive Officer | 50 | 01/01/2025 |
| Director of Finance/CFO | 63 | 29/04/2013 | |
| Chief Tech/Sci/R&D Officer | - | 01/09/2020 |
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 24/11/2011 | |
| Director/Board Member | 72 | 24/11/2011 | |
| Director/Board Member | 74 | 29/04/2013 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.06% | +4.19% | -0.02% | +17.01% | 1.26B | |
| +0.14% | +2.01% | +7.04% | +21.40% | 482M | |
| -1.09% | -1.09% | -20.65% | +26.83% | 65.34M | |
| Average | +0.04% | +1.70% | -4.54% | +21.75% | 602.32M | |
| Weighted average by Cap. | +0.74% | +3.42% | +1.12% | +18.54% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 45.69B 8.93B 7.81B 7.2B 6.64B 12.51B 860B 12.79B 86.09B 33.86B 421B 33.54B 32.81B 1,450B | 52.75B 10.31B 9.01B 8.32B 7.66B 14.45B 993B 14.77B 99.39B 39.09B 486B 38.72B 37.87B 1,674B |
| Net income | 1.54B 302M 264M 243M 224M 423M 29.06B 432M 2.91B 1.14B 14.23B 1.13B 1.11B 49B | 2.08B 406M 354M 327M 301M 568M 39.06B 581M 3.91B 1.54B 19.13B 1.52B 1.49B 65.85B |
| Net Debt | 8.07B 1.58B 1.38B 1.27B 1.17B 2.21B 152B 2.26B 15.2B 5.98B 74.37B 5.92B 5.79B 256B | 8.89B 1.74B 1.52B 1.4B 1.29B 2.43B 167B 2.49B 16.74B 6.59B 81.93B 6.52B 6.38B 282B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
- Stock Market
- Stocks
- RADL3 Stock
- DROG3 Stock
Choose MarketScreener Select your edition
All financial news and data tailored to specific country editions
